Pathophysiology of septic shock and multiple organ dysfunction syndrome and various therapeutic approaches with special emphasis on immunoglobulins

Therapeutic Apheresis

Volumn 5, Issue 2, 2001, Pages 115-122

  Werdan, Karl ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Intravenous immunoglobulins; Sepsis; Septic shock

Indexed keywords

ENDOTOXIN; EXOTOXIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; SUPERANTIGEN;

BACTERICIDAL ACTIVITY; CONFERENCE PAPER; CYTOKINE RELEASE; DISEASE ASSOCIATION; DOSE RESPONSE; HUMAN; INFLAMMATION; MEDIATOR RELEASE; MORBIDITY; MORTALITY; MULTIPLE ORGAN FAILURE; PARALYSIS; PATHOPHYSIOLOGY; PHAGOCYTOSIS; PRIORITY JOURNAL; SEPTIC SHOCK; TREATMENT PLANNING;

ANIMALS; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MORBIDITY; MULTIPLE ORGAN FAILURE; SEPSIS; SHOCK, SEPTIC;

EID: 0035004294     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-0968.2001.005002115.x     Document Type: Conference Paper

References (39)

1. Sir Isaac Newton, sepsis, SIRS, and CARS
2. Anti-inflammatory therapies to treat sepsis and septic shock. A reassessment
3. Use of intravenous immunoglobulin to prevent or treat infections in persons with immune deficiencies
4. Supplemental immune globulins in sepsis
5. Intravenous immunoglobulins and granulocyte colony-stimulating factor for the management of infection in intensive care units
6. Intravenous immune globulin has effects on superantigen-induced cytokine synthesis
7. Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages
8. In vitro inhibitory activity of tumor necrosis factor alpha and interleukin-2 of human immunoglobulin preparations
9. Prophylaxis of infection with intravenous immunoglobulins plus antibiotic for patients at risk for sepsis undergoing surgery for colorectal cancer: Results of a randomized, multicenter clinical trial
10. Reduced incidence of postoperative infections following intravenous application of an IgA- and IGM-enriched immunoglobulin preparation in anergic patients undergoing cardiac surgery
11. Comparison of early IgM-enriched immunoglobulin vs polyvalent IgG administration in score-identified post-cardiac surgical patients at high-risk for sepsis
12. Treatment of gram-negative septic shock with an immunoglobulin preparation. A prospective, randomized clinical trial
13. Letters to the Editor
14. Intravenous immunoglobulins: Prevention and treatment of disease
15. Supplemental immunoglobulin therapy in sepsis and septic shock - Comparison of mortality under treatment with polyvalent i.v.immunoglobutin versus placebo: Protocol of a multicenter, randomized, prospective, double-blind trial
16. Discussion forum
17. Early prediction of outcome in score-identified, post-cardiac patients at high risk for sepsis, using soluble tumor necrosis factor receptor-p55 concentrations
18. Cardiovascular parameters and scoring systems in the evaluation of response to therapy in sepsis and septic shock
19. Effects of early treatment with immunoglobulin on critical illness polyneuropathy following multiple organ failure and gram-negative sepsis
20. Bacterial lipopolysaccharide (LPS)-specific antibodies in commercial human immunoglobulin preparations: Superior antibody content of an IgM-enriched product
21. Polyvalent immunoglobulins for prophylaxis of bacterial infections in patients following multiple trauma - A randomized, placebo-controlled study
22. Einfluß einer adjuvanten immunglobulintherapie auf infektionen bei patienten einer operativen intensiv-therapie-station - Ergebnisse einer randomisierten kontrollierten studie
23. Cooperative group of additional immunoglobulin therapy in severe bacterial infections: Results of a multicenter randomized controlled trial in cases of diffuse fibrinopurulent peritonitis
24. Intravenous immunoglobulins in association with antibiotics: A therapeutic trial in septic intensive care unit patients
25. Auswirkungen von immunglobulin-substitution bei sepsis
26. Bewertung der intravenösen IgM-therapie bei schweren nosokomialen infektionen (Ergebnis einer kontrollierten randomisierten Studie)
27. Prophylaxe mit einem pseudomonas-immunglobulin bei brandverletzten
28. Early administration of intravenous immunoglobulins in the prevention of surgical and post-traumatic sepsis: A double blind randomized clinical trial
29. Adjuvante therapie mit pseudomonas-immunglobulin bei beatmeten patienten einer operativen intensivstation
30. Sepsis-therapie mit 5-S-immunoglobulinen
31. Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infections
32. Endotoxin concentrations and therapy with polyclonal IgM-enriched immunoglobulins in neutropenic cancer patients with sepsis syndrome: Pilot study and interim analysis of a randomized trial
33. High-dose intravenous IgG for treatment of severe surgical infections
34. Polyvalent immune globulins
35. Effects of high-dose IgG on survival of surgical patients with sepsis scores of 20 or greater
36. Anti-endotoxin therapy for fulminant meningococcal septicaemia: Pilot study
37. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome - A comparative observational study
38. Improved outcome of APACHE II score-identified escalating systemic inflammatory response syndrome in patients post cardiac surgery in 1996 compared to 1988-1990: The ESSICS-study pilot project